Hsbc Holdings PLC Cuts Stake in Sarepta Therapeutics, Inc. $SRPT

Hsbc Holdings PLC lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 22.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 80,678 shares of the biotechnology company’s stock after selling 23,022 shares during the quarter. Hsbc Holdings PLC owned 0.08% of Sarepta Therapeutics worth $1,387,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Y Intercept Hong Kong Ltd raised its holdings in shares of Sarepta Therapeutics by 1,736.5% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 870,181 shares of the biotechnology company’s stock valued at $14,880,000 after buying an additional 822,799 shares during the period. Aberdeen Group plc raised its stake in shares of Sarepta Therapeutics by 91.1% during the second quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company’s stock valued at $21,500,000 after purchasing an additional 592,125 shares during the period. Wellington Management Group LLP raised its stake in shares of Sarepta Therapeutics by 27.9% during the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock valued at $168,907,000 after purchasing an additional 577,848 shares during the period. EcoR1 Capital LLC lifted its position in shares of Sarepta Therapeutics by 67.8% during the first quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company’s stock worth $82,480,000 after purchasing an additional 522,386 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Sarepta Therapeutics by 151.4% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 615,441 shares of the biotechnology company’s stock valued at $10,524,000 after purchasing an additional 370,672 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

SRPT opened at $21.86 on Tuesday. The stock has a market cap of $2.29 billion, a P/E ratio of -7.26 and a beta of 0.54. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $131.31. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The company has a fifty day simple moving average of $20.85 and a 200 day simple moving average of $21.32.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The business had revenue of $399.36 million during the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The firm’s revenue was down 14.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.62 earnings per share. On average, research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on SRPT shares. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Sarepta Therapeutics to $12.00 and gave the stock a “sell” rating in a report on Friday, August 15th. Royal Bank Of Canada lifted their target price on Sarepta Therapeutics from $14.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. Robert W. Baird cut their price target on Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 4th. Mizuho raised Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and increased their price target for the company from $19.00 to $26.00 in a report on Wednesday, November 5th. Finally, HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a report on Monday, August 25th. Eight analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $33.75.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.